An alert isn't a prescription: what actually gets CKD tested and treated
A JASN review of two dozen studies found that alerts and home kits got more patients tested, but only programs with people doing the follow-through got more patients started on kidney-protective drugs.
🎧 Listen: Weekly · Nov 16, from 09:27.
The question
CKD affects more than one in seven adults, yet fewer than one in four people with type 2 diabetes get the recommended tests (an eGFR and a urine albumin), and only a small minority of those with diabetes and CKD are on an SGLT2 inhibitor. Health systems have tried many fixes. Which ones work?
What was done
A team at Duke, in North Carolina, searched for prospective studies with a comparison group that tried to improve CKD testing or treatment, and found 24, 21 of them in primary care, mostly in the US. It's a scoping review, so it maps the studies without pooling their results or grading their quality.
What they found
Testing was the easy part. Six of seven testing studies raised testing, using alerts in the electronic record, automatic lab orders or home urine test kits. But more testing rarely led to a diagnosis, a referral or a new prescription.
Treatment was harder. Only 5 of 17 treatment studies raised prescribing of kidney-protective drugs, and each of the five used active outreach or a clinician doing the follow-through: a pharmacist, a nurse practitioner or a care team. In one Veterans Affairs program, a pharmacist sent a letter, held a phone visit and could prescribe; new SGLT2 inhibitor starts nearly doubled. None of the studies that relied on alerts, prompts, decision support or registries without outreach raised prescribing, and neither did one-time letters.
The authors explain why: a test is a single, low-risk action a computer can order, while prescribing means checking eligibility and labs, discussing cost, getting prior authorization and having a conversation. An order is not a completed test, a prescription is not a drug started, and starting is not staying on it.
The limits
Most studies were in primary care and may not carry over to nephrology clinics. More than half of the treatment studies predate 2019 and tested ACE inhibitors and ARBs; only four targeted SGLT2 inhibitors, and none tested finerenone or GLP-1 receptor agonists.
Our take
If your system is about to buy another pop-up for CKD drugs, ask for a pharmacist's hours instead.
The source: Edmonston D, et al. Implementation Strategies to Improve CKD Testing and Delivery of Guideline-Directed Medical Therapy: A Scoping Review. J Am Soc Nephrol. Published online November 12, 2026. doi:10.1681/ASN.0000001324 Read the original
🎧 Listen: Weekly · Nov 16, from 09:27.
Physician-led, AI-assisted. Dr. Wael Hussein chooses every item NephSpace covers and reviews and edits every story before it is published. The first draft was written in our own words with AI (Claude, by Anthropic) from the full text of the paper and checked against our reading notes; Dr. Hussein then reviewed and edited it. For education and information only, not medical advice. Please talk to your own physician or care team about your health. Clinicians: read the original before changing practice. See our disclaimer and disclosures. Spotted an error? Tell us.